Latest News

{{header-clinical-trials-navigation}} Phase 4 Study of Exploring Circulating Tumor DNA (ctDNA) of Metastatic Castration-sensitive Prostate Cancer (mCSPC) Patients Receiving Apalutamide in Japan Condition: Metastatic Castration-sensitive Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04601441 Sponsor: Kindai University Phase: Phase 4 Eligibility: Age: minimum 20 Years maximum N/A Gender: Male Inclusion Criteria: Men aged ≥20 […]

{{header-clinical-trials-navigation}} A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, With an Observational Follow-up of PSMA-PET-Negative Patients Condition: Prostatic Neoplasms Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04557059 Sponsor: Janssen-Cilag Ltd. Phase: Phase 3 Eligibility: […]

{{header-clinical-trials-navigation}} Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients – a GETUG-AFU Phase III Randomized Controlled Trial Condition: Oligometastatic Hormone Sensitive Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04115007 Sponsor: UNICANCER Phase: Phase 3 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male Inclusion Criteria: Histologically proven adenocarcinoma of […]

{{header-clinical-trials-navigation}} Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation Therapy Condition: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8 Study Type: […]

We aimed to determine whether insurance expansions implemented through the Affordable Care Act (ACA) were associated with changes in coverage status, disease stage, and treatment of younger adults with testicular germ cell tumors (GCT).

Renal cell carcinoma (RCC) is one of the most common and life-threatening cancers in the world. Accumulating evidence suggest propofol inhibits the initiation and development of cancers. The main focus of the study was to explore the effect of propofol on RCC and its mechanism of action.

Papillary renal cell carcinoma (pRCC) represents the second most common kidney cancer and can be distinguished from other types based upon its unique histologic architecture and specific pattern of genomic alterations.

Objective: To determine prospectively the efficacy profile of 2 activity regimens of Lu-PSMA therapy in patients with progressive metastatic castrate resistant prostate cancer (mCRPC): 6.0 vs 7.4 GBq.

Major advances in delivery systems in recent years have turned radiotherapy (RT) into a more effective way to manage prostate cancer. Still, adjacency of organs at risk (OAR) can severely limit RT benefits.

A substantial proportion of men with localized prostate cancer (lPCa) later regret their treatment decision. We aimed to identify factors contributing to decisional regret. We conducted a longitudinal study, in which men with lPCa were surveyed at four measurement points: T0 (baseline) = prior to treatment; T1 = 6; T2 = 12; T3 = 18 months after baseline.